Aclarion announces Northwestern Medicine as first CLARITY trial site

Aclarion (ACON) announced Northwestern Medicine as the initial site in the pivotal CLARITY trial, which is designed to demonstrate Nociscan’s clinical and economic value in spine surgery. Aclarion recently announced that the CLARITY trial is fully funded and will be led by Dr. Nicholas Theodore of Johns Hopkins as principal investigator. The CLARITY trial is a prospective, randomized multi-center study evaluating patients who are scheduled to undergo surgical treatment of 1- or 2- level discogenic low back pain.